Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study)
2020-001623-13Phase 2Terminated
- Sponsor
- Uni-Pharma
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19), viral pneumonia and acute respiratory decompensation comparing Intravenous triiodothyronine with Placebo (2 arms). Primary endpoint: Successful weaning from cardiorespiratory support at 30 days. Started Apr 2020; status: terminated.
02
Drugs
liothyronine
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumoniaacute respiratory decompensation
Beyond the preview
Go deeper on 2020-001623-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001623-13.